Is NextCure Inc halal to invest in?

According to Musaffa's Shariah screening methodology, NextCure Inc (NXTC) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is NextCure Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes NextCure Inc using these criteria to determine its compliance status.

Can Muslims buy shares of NextCure Inc?

Muslim investors may consider investing in NextCure Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is NextCure Inc classified as NOT HALAL?

Musaffa determines the Shariah status of NextCure Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for NextCure Inc updated?

The Shariah compliance status of NextCure Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like NextCure Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of NextCure Inc?

You can check the latest Shariah compliance status of NextCure Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

NXTC Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 10, 2026

Report Source: 2025 Annual Report

NextCure Inc. Stock Analysis NXTC

United States Health Care Nano Cap Report: 2025 Annual

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company is headquartered in Beltsville, Maryland and currently employs 40 full-time employees. The company went IPO on 2019-05-09. The company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.

Key Statistics of NextCure Inc (NXTC)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$9.51$10.36

Today's Open

$9.90

Volume

48.74K

P/E Ratio (TTM)

52 Week Range

$4.60$15.74

Market Cap

33.18M

Avg. Volume

59.99K

Dividend Yield

Financial Metrics & Statements of NextCure Inc (NXTC)

FAQ's for NextCure Inc (NXTC)

According to Musaffa’s Shariah screening methodology, NextCure Inc (NXTC) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.